Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients

Approximately 45% of metastatic colorectal cancer (mCRC) patients with wild-type KRAS exon 2 are resistant to cetuximab treatment. We set out to identify additional genetic markers that might predict the response to cetuximab treatment. Fifty-three wild-type KRAS exon 2 mCRC patients were treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Hung-Chih, Thiam, Tan Kien, Lu, Yen-Jung, Yeh, Chien Yuh, Tsai, Wen-Sy, You, Jeng Fu, Hung, Hsin Yuan, Tsai, Chi-Neu, Hsu, An, Chen, Hua-Chien, Chen, Shu-Jen, Yang, Tsai-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008360/
https://www.ncbi.nlm.nih.gov/pubmed/26989027
http://dx.doi.org/10.18632/oncotarget.8076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5008360/
https://www.ncbi.nlm.nih.gov/pubmed/26989027
http://dx.doi.org/10.18632/oncotarget.8076

Ejemplares similares